X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
1. Acetic Acid, Calcium Salt
2. Acetic Acid, Calcium Salt (2:1)
3. Phoslo
1. 62-54-4
2. Calcium Diacetate
3. Acetic Acid, Calcium Salt
4. Lime Acetate
5. Phoslo
6. Lime Pyrolignite
7. Acetate Of Lime
8. Brown Acetate
9. Acetic Acid Calcium Salt
10. Gray Acetate Of Lime
11. Brown Acetate Of Lime
12. Phoslyra
13. Calcium;diacetate
14. Calcium Ethanoate
15. Fema No. 2228
16. Calcarea Acetica
17. Calcium(ii) Acetate
18. Acetic Acid, Calcium Salt (2:1)
19. Calcium Acetate Anhydrous
20. Calcium Acetate, Anhydrous
21. Chebi:3310
22. Ins No.263
23. Y882yxf34x
24. Teltozan
25. Sorbo-calcion
26. Vinegar Salts
27. Gray Acetate
28. Ins-263
29. Phoslo Gelcaps
30. Calcium Di(acetate)
31. E-263
32. Ca(oac)2
33. Eliphos
34. Sanopan
35. Ccris 4921
36. Hsdb 928
37. Einecs 200-540-9
38. Calcium Acetate [usp:jan]
39. Unii-y882yxf34x
40. Ai3-02903
41. Calcium Acetate Salt
42. Phoslo (tn)
43. Calcium Acetate, Fcc
44. Calcium Acetate (usp)
45. Ec 200-540-9
46. Calcium Acetate 23% 10m
47. Schembl23872
48. Calcium Acetate [ii]
49. Calcium Acetate [mi]
50. Calcium Acetate [fcc]
51. Calcium Acetate [fhfi]
52. Calcium Acetate [hsdb]
53. Calcium Acetate [inci]
54. Calcarea Acetica [hpus]
55. Calcium Acetate [vandf]
56. Calcium Acetate [mart.]
57. Chembl1200800
58. Dtxsid0020234
59. Calcium Acetate [usp-rs]
60. Calcium Acetate [who-dd]
61. Calcium Acetate (fragrance Grade)
62. Amy23411
63. Mfcd00012448
64. Calcium Acetate [orange Book]
65. Akos015904560
66. Calcium Acetate [ep Monograph]
67. Calcium Acetate [usp Monograph]
68. Db00258
69. E263
70. Ft-0623376
71. Ft-0623377
72. D00931
73. Calcium Acetate, Anhydrous [ep Impurity]
74. Cis,cis-1,3,5-cyclohexanetricarboxylicacid
75. Q409251
76. Calcium Diacetate, Cac - Acetic Acid, Calcium Salt
77. J-519530
| Molecular Weight | 158.17 g/mol |
|---|---|
| Molecular Formula | C4H6CaO4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 0 |
| Exact Mass | 157.9891995 g/mol |
| Monoisotopic Mass | 157.9891995 g/mol |
| Topological Polar Surface Area | 80.3 Ų |
| Heavy Atom Count | 9 |
| Formal Charge | 0 |
| Complexity | 25.5 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
| 1 of 6 | |
|---|---|
| Drug Name | Calcium acetate |
| PubMed Health | Calcium Acetate (By mouth) |
| Drug Classes | Calcium Supplement, Phosphate Binder |
| Drug Label | Each white, round tablet (stamped CYP910) contains 667 mg calcium acetate, USP (anhydrous; Ca(CH3COO)2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, polyethylene glycol 8000 NF; sodium lauryl sulfate, NF; and crospovidone, NF. ELIPHOS... |
| Active Ingredient | Calcium acetate |
| Dosage Form | Tablet; Capsule |
| Route | Oral |
| Strength | eq 169mg calcium |
| Market Status | Prescription |
| Company | Amneal Pharms; Paddock; Invagen Pharms; Roxane |
| 2 of 6 | |
|---|---|
| Drug Name | Phoslo gelcaps |
| Active Ingredient | Calcium acetate |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | eq 169mg calcium |
| Market Status | Prescription |
| Company | Fresenius Medcl |
| 3 of 6 | |
|---|---|
| Drug Name | Procalamine |
| Active Ingredient | calcium acetate; sodium chloride; magnesium acetate; sodium acetate; phosphoric acid; glycerin; potassium chloride; Amino acids |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 200mg/100ml; 150mg/100ml; 26mg/100ml; 54mg/100ml; 120mg/100ml; 3gm/100ml; 41mg/100ml; 3% |
| Market Status | Prescription |
| Company | B Braun |
| 4 of 6 | |
|---|---|
| Drug Name | Calcium acetate |
| PubMed Health | Calcium Acetate (By mouth) |
| Drug Classes | Calcium Supplement, Phosphate Binder |
| Drug Label | Each white, round tablet (stamped CYP910) contains 667 mg calcium acetate, USP (anhydrous; Ca(CH3COO)2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, polyethylene glycol 8000 NF; sodium lauryl sulfate, NF; and crospovidone, NF. ELIPHOS... |
| Active Ingredient | Calcium acetate |
| Dosage Form | Tablet; Capsule |
| Route | Oral |
| Strength | eq 169mg calcium |
| Market Status | Prescription |
| Company | Amneal Pharms; Paddock; Invagen Pharms; Roxane |
| 5 of 6 | |
|---|---|
| Drug Name | Phoslo gelcaps |
| Active Ingredient | Calcium acetate |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | eq 169mg calcium |
| Market Status | Prescription |
| Company | Fresenius Medcl |
| 6 of 6 | |
|---|---|
| Drug Name | Procalamine |
| Active Ingredient | calcium acetate; sodium chloride; magnesium acetate; sodium acetate; phosphoric acid; glycerin; potassium chloride; Amino acids |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 200mg/100ml; 150mg/100ml; 26mg/100ml; 54mg/100ml; 120mg/100ml; 3gm/100ml; 41mg/100ml; 3% |
| Market Status | Prescription |
| Company | B Braun |
... Used to restrict phosphate absorption in patients with chronic renal failure and oxalate absorption in patients with inflammatory bowel disease.
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1523
Calcium acetate is indicated in patients with end-stage renal failure to lower serum phosphate concentrations. It does not promote aluminum absorption. /Included in US product labeling/
USP. Convention. USPDI - Drug Information for the Health Care Professional. 19th ed. Volume I.Micromedex, Inc. Englewood, CO., 1999. Content Prepared by the U.S. Pharmacopieal Convention, Inc., p. 719
Except under special circumstances, this medication /calcium acetate/ should not be used when the following medical problem exists: hypercalcemia (calcium acetate may exacerbate the condition).
USP. Convention. USPDI - Drug Information for the Health Care Professional. 19th ed. Volume I.Micromedex, Inc. Englewood, CO., 1999. Content Prepared by the U.S. Pharmacopieal Convention, Inc., p. 719
Concurrent use /with digitalis glycosides/ is not recommended because calcium acetate may cause hypercalcemia, which could precipitate cardiac arrhythmias.
USP. Convention. USPDI - Drug Information for the Health Care Professional. 19th ed. Volume I.Micromedex, Inc. Englewood, CO., 1999. Content Prepared by the U.S. Pharmacopieal Convention, Inc., p. 719
Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.
FDA Label
Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.
Chelating Agents
Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)
V - Various
V03 - All other therapeutic products
V03A - All other therapeutic products
V03AE - Drugs for treatment of hyperkalemia and hyperphosphatemia
V03AE07 - Calcium acetate
Absorption
40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.
Route of Elimination
Calcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.
Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.
Market Place
